Отключить феруловую кислоту для неврологических заболеваний и приспособить наноформуляцию для ускорения передачи мозга.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Andrade Paulo Ricardo Alves, Motta Raíssa Coelho, Fonseca-Santos Bruno
Аннотация
Оригинал публикации
Unlocking ferulic acid for neurological diseases and tailoring of nanoformulations to advance its brain delivery.
Mental disorders represent a significant global health challenge, with a high prevalence and substantial impact on individual well-being. Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS) and various mood disorders, contribute significantly to the burden of neurological conditions worldwide. Identifying novel drug targets and exploring natural product-based molecules have become essential priorities in advancing treatment strategies for these complex diseases. Nanoencapsulation technology has emerged as a valuable tool to increase the stability, solubility, and bioavailability of natural products, thus improving their efficacy in treating neurological disorders. By encapsulating natural compounds such as ferulic acid (FA) in nanoscale delivery systems, researchers have aimed to overcome challenges related to poor solubility and bioavailability, ultimately enhancing therapeutic outcomes. In this review, we examine recent advancements focused on the therapeutic potential of FA in AD, PD, MS, brain cancer, depression (DP), anxiety (AX), and epilepsy (EP). Furthermore, we explored the use of nanoscale delivery systems to optimise the delivery of FA for improved treatment efficacy. We aim to inspire discoveries and innovative approaches to address neurological diseases by highlighting current progress and future directions in this field with FA.